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Abstract
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure that is considered a
good alternative to surgical aortic valve replacement (sAVR) in selected patients. Our aim is to determine the baseline,
procedural characteristics and one-year clinical outcomes of our TAVI registry.
METHODS: This study is a retrospective observational analysis of a prospectively designed cohort comprising 81
consecutive patients treated at Mohammed bin Khalifa Cardiac Centre (MKCC) who were enrolled in Bahrain TAVI
registry from February 2014 to February 2019. The clinical endpoints were deﬁned according to the updated Valve
Academic Research Consortium-2 (VARC-2) consensus document.
RESULTS: Out of the 81 patients included in our study, there were 37 (45.7%) males. The mean age was 76.4 ± 8.9 years
with a mean Logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE II) of 4.1 ± 2.5 and a mean
Society of Thoracic Surgery (STS) Risk Score of 4.2 ± 3.5. Evolute-R valve was used for 36 (44.4%) patients, Edward
Sapien for 26 patients (32.1%), and Core valve for 19 patients (23.5%). At one year follow up, all-cause death was reported
in three (3.7%) patients; none of them was cardiovascular mortality. As per VARC-II criteria, no cases fulﬁlled the criteria
of valve dysfunction but TAVI-related complications (i.e., TAV-in-TAV deployment) were reported in four (4.9%) cases.
One (1.2%) case of major bleeding was encountered but no patient experienced life-threatening bleeding. Major vascular
complications were documented in two patients (2.5%) only. Signiﬁcant Acute Kidney Injury (AKI) occurred in two
(2.5%) patients, both classiﬁed as stage-2 but no one deteriorated to stage-3 or hemodialysis. Seven (8.6%) patients
required permanent pacemakers, and all were implanted during the index admission for TAVI. One patient (1.2%) had
stroke and all survivors completed one-year follow up.
CONCLUSION: The TAVI program in Bahrain is encouraging and corresponds to the ﬁnest international centers
outcomes in terms of procedural success and complications rate.
Keywords: Aortic stenosis, Aortic valve replacement, Corevalve, Evolute-R, Edward Sapien, Transcatheter aortic valve
implantation

1. Introduction

T

he Kingdom of Bahrain has experienced a
steady advancement in socio-economic status and healthcare systems over the past decades
[1]. As a consequence, life expectancy above 65

years of age has increased and the population is
aging swiftly [2]. Many chronic medical conditions, like diabetes mellitus, systemic and pulmonary hypertension, renal and liver failure,
coronary and peripheral artery disease, lung disease and cancer frequently coexist in geriatrics,
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which constitute a high surgical risk, compared to
the younger population.
Aortic stenosis is the most commonly encountered
valvular heart disease and a substantial surge in its
incidence is anticipated in the coming decades
because of the progressive aging of mankind [3]. In
symptomatic sever aortic stenosis (AS), surgical
aortic valve replacement improves survival, in the
absence of major comorbidities, with relatively low
operative mortality [4]. However, in clinical practice,
surgeons turn down 20%e40% of patients with severe symptomatic AS owing to prohibitive surgical
risk [5]. For these patients, a less invasive option will
be extremely valuable.
Transcatheter aortic valve implantation (TAVI) is a
rapidly evolving procedure, in which a bioprosthetic
valve is inserted through a catheter and implanted
within the diseased native aortic valve. Since 2002,
when Alain Cribier performed the ﬁrst in-man implantation, TAVI has popped up as a practical, substitute treatment modality of stenotic aortic valves
and exhibited outcomes as good as sAVR in patients
who are considered inoperable or at intermediate to
high surgical risk [6,7]. Recently, PARTNER-3 and
Evolute Low-risk trial determined that TAVI is noninferior to sAVR in low-risk patients [8,9]. The
tremendous government ﬁnancial support and the
strong conviction in TAVI of Bahraini interventional
cardiologists were behind the success of TAVI in our
kingdom but, in spite of the wide acceptance of the
TAVI procedure, there have been hardly any publications on TAVI from our county and hence, we
thought to describe our experience, which was
launched at MKCC early in 2014. This study is
unique in that it has captured every TAVI performed
in the kingdom of Bahrain and includes the entire
learning curve and early experience without any
publication bias as it represents individuals undergoing TAVI in the real world. Furthermore, treatment strategy that works very well in one centre may
not be appropriate in another one therefore, it is felt
that sharing local experience and outcomes would be
crucial to provide roadmap to centers planning to
start TAVI program.

2. Materials and methods
2.1. Setting
This is a single-center retrospective study
including patients who underwent TAVI procedure
between February 2014 and February 2019 at
Mohammed bin Khalifa Cardiac Centre (MKCC) in
the kingdom of Bahrain; which is the only tertiary
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Abbreviation list
AS
aortic stenosis
CT
Computed tomography (CT)
CVA
Cerebrovascular accident
ECG
Electrocardiogram
Euroscore
European system for cardiac operative
risk evaluation
LVEF
Left ventricular ejection fraction
MKCC Mohammed bin Khalifa Cardiac Centre
PPM
Permanent pacemaker
sAVR
Surgical aortic valve replacement
STS
Society of Thoracic Surgery
TAVI
Transcatheter aortic valve implantation
TEE
Transesophageal echocardiography
TTE
Transthoracic echocardiography
VARC
Valve Academic Research Consortium-2

cardiac center in Bahrain where all TAVI procedures are performed.
2.2. Study population and heart team
All patients have been selected for TAVI after
multidisciplinary team review by a dedicated heart
team of invasive and non-invasive cardiologists,
cardiac surgeons and cardiac anesthetists at our
institution. Heart Team members work closely
together and meet regularly to discuss the most
appropriate treatment options based on the clinical
data, technical aspects, local experience and recommendations from the guidelines to determine the
most appropriate individualized therapy and
consequently set-up a center of excellence where
innovative therapies can be further developed and
the future generation of heart valve specialists
effectively trained.
2.3. Eligibility
Inclusion criteria were patients with symptomatic
severe aortic stenosis, deemed at high risk for conventional surgical aortic valve replacement. Exclusion criteria were patient's refusal of informed
consent to participate in the registry or lack of capacity to consent and/or high probability of nonadherence to follow-up requirements (e.g. visitors
from abroad).
2.4. TAVI procedure
Baseline investigations included routine blood
tests, cardiac markers, chest radiography, electrocardiogram (ECG), transthoracic echocardiography
(TTE) and if indicated we proceed with

ORIGINAL ARTICLE

JOURNAL OF THE SAUDI HEART ASSOCIATION 2020;32:434e439

436

JOURNAL OF THE SAUDI HEART ASSOCIATION 2020;32:434e439

ORIGINAL ARTICLE

transesophageal echocardiography (TEE), selective
coronary angiography and computed tomography
(CT) of the aortic valve, aorta and iliofemoral access.
Transthoracic echocardiography was used to
measure aortic valve pressure gradient, aortic
regurgitation grade and left ventricular ejection
fraction (LVEF) before and after TAVI. Mean aortic
gradient was further conﬁrmed during cardiac
catheterization with invasive measurement before
and after the procedure.
Tortuosities, as well as the amount of calciﬁcations
were analyzed in CT to assert the feasibility for a
transfemoral approach and to evaluate the aortic
root anatomy including aortic annulus measurements, the valve morphology, commissural fusion,
calciﬁcation distribution and coronary artery height
from the hinge points.
AVI was performed via either transfemoral or
subclavian routes with implantation of selfexpanding Medtronic CoreValve and Evolute-R
valves from February 2014 to January 2018 then we
switched to balloon-expandable Edwards Sapien
valves from January 2018 onward. A transfemoral
ﬁrst policy was applied, if non-applicable due to any
reason then alternate access routes (mainly subclavian) were considered. All procedures conducted
with sedation and local anesthesia.
Patients stayed in the intensive care unit during
the ﬁrst 24e48 h after the procedure and were then
transferred to the cardiology ward, if there were no
complications. Follow up was considered complete
one-year after the TAVI procedure.
2.5. Outcomes

windows to perform the statistical analysis and for
producing graphs and plots.

3. Results
Out of the 81 patients included in our study, there
were 37 (45.7%) males. The mean age was 76.4 ± 8.9
years (See Fig. 1). In terms of preoperative predicted
risk of surgical mortality, the mean Logistic European System for Cardiac Operative Risk Evaluation
(EuroSCORE II) was 4.1 ± 2.5 and the mean Society
of Thoracic Surgery (STS) Risk Score was 4.2 ± 3.5.
The femoral artery was the most common access
site and was utilized in 97.5% of the cases.
Regarding valve types, Evolute-R valve was used in
36 (44.4%) patients, Edward Sapien in 26 patients
(32.1%) and Corevalve in 19 patients (23.5%) (See
Fig. 2). The full analysis of baseline characteristics of
the study population is depicted in Table 1.
During one-year follow up, three (3.7%) cases of
all-cause death were reported, both were non-cardiovascular mortality. As per VARC-II criteria, no
cases fulﬁlling the deﬁnition of valve dysfunction
were encountered but TAVI-related complications
(i.e. TAV-in-TAV deployment) were reported in four
(4.9%) cases. One (1.2%) event of major bleeding
was documented but no patient experienced procedural related life-threatening bleeding. Eight
(9.8%) patients had vascular complications; the
majority were minor and observed in six (7.4%)
patients, while major vascular complications were
documented in two patients (2.5%) only.
Signiﬁcant Acute Kidney Injury (AKI) occurred in
two (2.5%) patients, both classiﬁed per VARC-II
criteria as stage-2 but no one deteriorated to stage-3

Endpoints at one-year follow up comprised allcause death, cardiovascular death, valve dysfunction and the need for permanent pacemakers (PPM).
Other studied outcomes were procedural related
myocardial infarction, cerebrovascular accidents,
major bleeding, major vascular access complications
and acute kidney injury. The widely accepted Valve
Academic Research Consortium (VARC-2) Criteria
were used to deﬁne and assess procedural success,
safety end points and clinical outcomes [10].
2.6. Statistical analysis
Categorical data were expressed as numbers and
percentages. Continuous variables were reported as
mean and standard deviation for normal distributions, or as the median with minimum and
maximum values for skewed distributions. We used
the statistical software package SPSS-24 for
Fig. 1. Age and gender distribution among TAVI patients in Bahrain.

Table 2. Clinical outcomes of Bahrain TAVI registry.
Endpoints at one-year Follow up
All-cause mortality, no. (%)
Cardiovascular mortality, no. (%)
Valve dysfunction, no. (%)
Pacemaker implantation, no. (%)
Periprocedural complications
Bleeding, no. (%)
Life threatening
Major
Vascular complications, no. (%)
Major
Minor
Acute kidney injury, no. (%)
Stage 1
Stage 2
Stage 3
Myocardial infarction (<72 h), no. (%)
Cerebrovascular accident, no. (%)
TAV-in-TAV deployment, no. (%)

3 (3.7%)
0
0
7 (8.6%)
0
1 (1.2%)
2 (2.5%)
6 (7.4%)
5
2
0
0
1
4

(6.2%)
(2.5%)
(1.2%)
(4.9%)

Fig. 2. Types of valves in Bahrain TAVI registry.

or hemodialysis. Seven (8.6%) patients had high-

Table 1. Baseline and procedural characteristics (81 patient).
Demographic variables
Age (years), mean ± SD
Male, no. (%)
BMI (kg/m2) mean ± SD
Body surface area (m2) mean ± SD
Clinical variables
Diabetes mellitus, no. (%)
Systemic Hypertension, no. (%)
Dyslipidaemia, no. (%)
Coronary artery disease, no. (%)
Cerebrovascular accident, no. (%)
Haemodialysis, no. (%)
Peripheral vascular disease, no. (%)
Chronic obstructive airway disease, no. (%)
Pre-procedural investigations
Aortic valve area (cm2), mean ± SD
Non-invasive gradient (mmHg), mean ± SD
Ejection fraction (%), mean ± SD
Creatinine (umol/L), mean ± SD
Glomerular ﬁltration rate (mL/min) mean ± SD
Haemoglobin (g/dL) mean ± SD
Risk assessment of surgical mortality
Euroscore II score (%), mean ± SD
STS score (%), mean ± SD
Procedural characteristics
Access site
Femoral, no. (%)
Subclavian, no. (%)
Device
CoreValve, no. (%)
Evolute-R, no. (%)
Edward Sapien, no. (%)
Invasive mean gradient
Pre-TAVI (mmHg), mean ± SD
Post-TAVI (mmHg), mean ± SD
Aortic regurgitation index, mean ± SD

76.4 ± 8.9
37 (45.7%)
31.6 ± 6.6
1.8 ± 0.21
52 (64.2%)
71 (87.6%)
63 (77.8%)
63 (77.8%)
8 (9.9%)
3 (3.7%)
8 (9.9%)
5 (6.2%)
0.67
44.3
53.1
99.7
53.5
11.6

±
±
±
±
±
±

0.19
15.0
13.3
84
11.5
1.6

4.1 ± 2.5
4.2 ± 3.5
79 (97.5%)
2 (2.5%)
19 (23.5%)
36 (44.4%)
26 (32.1%)
43.7 ± 19.1
1.9 ± 3.3
28.0 ± 7.8

degree atrioventricular block necessitating PPM
implantation; all were implanted during the index
admission for TAVI. One patient (1.2%) had cerebrovascular accident (CVA) two weeks after valve
implantation. All survivors completed one year of
follow up. The clinical outcomes are summarized in
Table 2.

4. Discussion
Our study describes the experience of TAVI in the
one and only TAVI performing cardiac center in
Bahrain. The Kingdom of Bahrain is an island in the
Arabian Gulf and has approximately one and a half
million inhabitants. Despite being one of the
smallest countries in Asia, Bahrain has the entire
health service expenditure per person comparable
to leading European countries [1,2and11].
According to the latest WHO age structure estimate (July 2018), only 3.0% of the population in
Bahrain were above 65 years of age (this age category constitutes up to 18%e20% in many western
countries), with comparable numbers of both genders in a ratio of 1.01 and estimated life expectancy
of 76.9 years for males and 81.5 years for females
[12]. The small number of inhabitants belonging to
this age group clearly explains the low volume of
TAVI cases in Bahrain.
The Placement of AoRTic TraNscathetER Valve
(PARTNER) Trial is a very well-designed, meticulously executed, prospective randomized trial that
demonstrated that TAVI with the Edwards Sapien
valve was not inferior to standard surgical aortic
valve replacement in patients with symptomatic
sever aortic stenosis who are high risk for surgical
therapy (cohort A), and was superior to medical
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therapy in the treatment of inoperable patients with
aortic stenosis (cohort B) [13].
Our study population matched the same risk
proﬁle of PARTNER-II Trial (TAVI vs. sAVR in intermediate risk patients), with mean STS score of
5.8 ± 2.1 compared to 4.2 ± 3.5 in our cohort 13 (13a,
b, 14). PARTNER-II showed that, aside from patients
after TAVI resuming normal daily activities earlier
than patients who underwent sAVR, TAVI is associated with lower incidence of the combined
endpoint of mortality, all-stroke, and aortic regurgitation at one-year [14].
Comparing our baseline characteristics with
PARTNER-II trial, we found that our patients were
slightly younger (76.4 ± 8.9 vs. 81.5 ± 7.7 years) with
less percentage of males (45.7% vs. 54.2%) [13,14].
In line with almost all TAVI trials, our invasive
and echocardiography data demonstrated instant
reduction in the pressure gradient across AV, as
well as improvement of systolic pulmonary artery
pressure [15].
In what could be a reﬂection of the successful
evolution of TAVI procedure worldwide, PARTNER-II showed 12.3% all-cause mortality and 7.1%
cardiovascular mortality after TAVI, compared to
3.7% and 0% in our study, respectively [14]. In
addition, the experience of the operators should be
considered and the acquisition of the cutting-edge
evidence-based techniques and devices as well as
relatively lower-risk patients.
We also noted the low incidence of major vascular
complications (2.5% vs. 7.9%) and major bleeding
(1.25% vs. 10.4%) in comparison to PARTNER-II;
this indicated that our team was very careful in
patient selection and implementation of all possible
precautions to avoid such complications, especially
in that we learned from previous studies the negative impact of such complications on clinical outcomes of TAVI patients.
Furthermore, our registry showed 1.25% incidence
of cerebrovascular accidents which is relatively low
compared to PARTNER-II trial (5% stroke rate) [16],
but comparable to recent studies including a report
from the American College of Cardiology (ACC)
Transcatheter Valve Therapies registry (n ¼ 12,182)
that reported less than 2.5% stroke rate [17].
While AKI was observed in seven (8.6%) of our
patients, the true incidence may be underreported
as the timing for the diagnosis of AKI is extended
from 72 h to 7 days in the latest VARC criteria and
many patients in our registry were discharged
before completing seven days post TAVI. Two
(2.5%) had signiﬁcant AKI classiﬁed per VARC-II
criteria as stage-2 (i.e. increase in serum creatinine

to 200%e299% (2.0e2.99  increase compared with
baseline) [10], but no one progressed to stage-3 or
required hemodialysis and both patients recovered
completely during follow up.
The incidence of new PPM was almost similar to
PARTNER-II (8.6% vs. 9.9%) [15]; our seven cases
were all implanted during index admission for TAVI
and distributed as follows: two (10.5%) in Corevalve
group; three (8.3%) in Evolute-R group; and two
(7.6%) in Edward Sapien group. Our study is deﬁnitely underpowered to determine any association
between the need for PPM and the type of implanted device but the trend suggests that self-expandable Medtronic CoreValves are at higher risk [14,15].
These observations are supported by data from
large registries in which Corevalve implantation
was associated with more frequent development of
conduction abnormalities, which is likely due to
deep implantation that occurs more frequently in
Corevalve than in Edward Sapien [18,19]. Lenders
et al. showed that the use of a newer delivery system
might help to solve this problem [20].
While there were four cases of TAVI-related
complications in terms of severe aortic regurgitation
discovered promptly after deployment of ﬁst-valve,
all managed successfully with implantation of second valve during the index procedure (TAV-in-TAV
deployment), and we did not encounter any incidence of prosthetic valve dysfunction at one-year
follow up using patient's own initial post-implant
study as a reference for serial comparison.

5. Conclusion
The TAVI program in Bahrain is encouraging and
corresponding to the ﬁnest international centers
outcomes in terms of procedural success and complications rate.
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